US and UK Finalize Duty-Free Accord on Prescription Drugs.

Medicine exports between the US and UK
Stock image of pharmaceutical shipments.

The United Kingdom and the United States have established a landmark commercial pact that will guarantee no levies on British medicine products being sold in the American market.

The Terms of the Deal

As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the public health system. This pledge guarantees that duties on these crucial goods will be held at nothing for a period of 36 months.

This deal is in response to earlier threats to dramatically increase duties on branded drug imports, with increases mentioned up to 100%.

"This agreement with the United Kingdom bolsters the global environment for innovative medicines and establishes long-overdue equity to American-British drug exports," a release noted.

Commercial Impact

Pharmaceuticals are one of the the United Kingdom's biggest export categories to the US, which is easily the biggest market for large companies like GSK and AstraZeneca.

Export figures show that in the 12 months prior to September, the UK exported drugs worth ÂŁ11.1bn to the US. This amount represented a significant portion of total UK exports in that period.

"This guarantee protects jobs, stimulates funding and facilitates the UK to become a worldwide center for biotech and pharma," a government official commented.

Detailed British Pledges

The pact includes several notable commitments from the United Kingdom:

  • Price Threshold Increase: The UK will lift the price threshold at which it considers new therapies to be prohibitively costly by 25%.
  • Boosted Medicine Funding: There is a aim to increase total public funding on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
  • Refund Ceiling: The sum drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, refunds were more than twenty percent.

Recent Tensions

The pact takes place against a ongoing row between the sector and the UK government over medicine costs and regulatory access.

The disagreement were intensified by arguments that American patients were charged several times more for the identical medicines than people in the Britain and the EU.

Over the last 18 months, several large pharmaceutical investments in the UK have been halted or cancelled, while substantial expansions have been announced toward American operations.

A senior figure publicly accepted that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the last ten years.

Brenda Garcia
Brenda Garcia

A tech enthusiast and digital strategist with over a decade of experience in web development and online marketing.